Publishing options:
Swiss institute associated authors

Key information

1. How do we determine eligibility of the article for the Swiss agreement?

- The submission date of the article should be on or after 1st January 2020
- The corresponding author must be from a participating institute
- The article must be from a participating journal

2. Why do we use submission date as the eligibility criteria?

- The submission date is the only stable point the publishing process. Acceptance and publication dates vary based on the journal processes

- The author controls the submission date. This gives the author not just control, also transparency and predictability however long or short the journal will take for the review and publication process

Key information

3. Role of the institutional librarian in the Elsevier OA Platform (EOAP)

- By the time the article in is your EOAP, we have published the first version of your article in Science Direct (within 48 hours of acceptance)

- You therefore do not approve the publication of the article, you validate whether the corresponding author can make use of the APC fund as part of the agreement

Corresponding author receives an email post acceptance with a link an unique link to complete the author journey and choose publishing options

Click on 'Complete the Rights and Access information form' or make changes and resubmit link in case you already completed the journey previously



Elsevier: Author journey demo for Swiss institutions

Corresponding author
E-mail address
Journal Fuel
Our reference JFUE237124
PII S0016-2361(19)31362-6

Welcome Dr
To help us finalize the publication of your article please complete the publishing form(s) below.
Note: you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

- **Purchase Order Number**
  If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.
- **Tax Exemption Number** and **Tax Exemption Certificate** if applicable to your institution.

For Bank and company address details, see the Information you may need to supply to complete the options.

Rights and Access

Complete the Rights and Access information form

Elsevier supports responsible sharing. To find out how you can share your article, please visit our Sharing Policy page.
For information on author rights visit Elsevier's Author Rights pages.
For information on publishing open access with Elsevier visit elsevier.com/openaccess.



- **Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Swiss agreement**
- **In this case author chooses University of Geneva**



Corresponding author also adds the co-author affiliation details


1 Corresponding Author
2 Co-Author
3 Research Funders
4 Publishing Options
5 Review Order
6 Confirmation
Elsevier: Author journey demo for Swiss institutions
Did the research in this article receive funding?
Yes
No
Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case it is Milliman
Funder Details
Please provide details of the organization(s) that funded the research. For tips on searching for an organization please visit our Support Center.
If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.
Organization name*
Milliman
Grant/Contract numbers*
GT1234
+ Add grant/contract number
+ Add another organization
Previous
Save and Continue >

- **Based on the affiliation details, the author sees the Publishing Options. Gold OA option is followed by Subscription option and we make it clear that agreement covers full APC**
- **If the librarian at the consortium rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice**
- **Author selects Gold OA**



- **In case of OA, author selects the CC License**
- **For Swiss agreement, we present CC BY followed by CC BY NC ND.**
- **Author selects CC BY license in this case**

Elsevier: Author journey demo for Swiss institutions

Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our Support Hub for additional help.

CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

Read more about CC BY 4.0

CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

Read more about CC BY-NC-ND 4.0

Previous

Save and Continue >



Author selects the rights

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Licenses — 6 Rights — 7 Publishing Agreement — 8 Review Order — 9 Confirmation

System presents author with the Journal License Publishing Agreement

Elsevier: Author journey demo for Swiss institutions

Elsevier Ltd

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier Ltd an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier Ltd shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

Authors agrees to the Journal License Publishing Agreement

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors' institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Ltd ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright.

☑ **I have read and agree to the terms of the License Agreement.**



- **This is the summary page explaining the choices the author made in the publishing journey**
- **Corresponding author and coauthors receive a copy of summary via email**
- **Once the author clicks on finish, article becomes OA on SD within 24 hours**
- **EOAP admin at the institution will receive a notification within 48 hours**

Review Order

Research Funders	Milliman Grant numbers: GT1234
Publishing Option	Gold Open Access *
User License	CC BY 4.0
Publishing Agreement	• I am one author signing on behalf of all co-authors of the manuscript

I may share my final published article widely in accordance with the user License that I have selected.
Further details on Elsevier Sharing Policy here.

*If your institution does not approve paying the APC, you will receive an invoice for the APC of EUR 3,460.00 (ex. VAT). You then have the option to either pay the APC invoice or publish your article free of charge under the subscription model. To publish your article under the subscription model, contact Researcher Support within two weeks of the invoice date. Elsevier will send the invoice to the email address you have provided on your author profile.

21 May 2020

Previous

Finish >

Overview of the improvements to the author journey for the Swiss corresponding authors

#	Improvement	Description	Timeline and Result
1	Improvements to the non-validation text	In Hybrid journals, we made it clear that the authors that publish free of charge under subscription if the institution rejects the APC request	Implemented in May 2020
2	Removed the copy paste option in the author affiliation field	To make a match to the institution, the authors need to select the institution name from the search. We recently removed the copy paste option in April 2020 that was resulting in authors not selecting the institution	Implemented in April 2020. Since then affiliation matching has improved from 91 to 94%
3	Presenting German and French variations of the institution names in the affiliation field	The authors can now search using the German and French in the author journey and we will match them to the agreement	This went live on 22nd June 2020. We hope that this will improve the matching even further as it improves the search experience for our authors
4	Add an extra category of German names where we have an Umlaut	On top of showing the German versions of the names, we will also present an alternate way of spelling the names with Umlaut (replacing umlaut with "ae", "oe", "oe" and letter "ß" with "ss")	Planned to implement in Q4 2020
5	Process to match eligible authors to the agreement where there was no institution match	On a biweekly basis, we identify the authors who were not matched to the agreement because the author did not select it from the drop down search. As part of our after care process, we update the insttitute name in the author journey, contact these authors so they can activate OA under the agreement	Implemented in May 2020 so we can offer the agreement to all the eligible authors
6	Updates to Gold OA text with recommendations from our UX language expert and the Swiss consortium	Clear and concise information to the authors	Early July. The OA uptake has gone up from 69% in May 2020 to 81% in August 2020

ELSEVIER

Thank you

- **Screenshot showing the German variations of the Paul Scherrer institute**



- **Publishing options page when we implemented in author journey in January 2020**



- **Publishing options page in May 2020 showing the new validation text and short Gold OA text**